365 results about "Slow release drug" patented technology

The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions.

This invention provides for biocompatible and biodegradable syringeable liquid, implantable solid, and injectable gel pharmaceutical formulations useful for the treatment of systemic and local disease states.

A formulation to treat ocular conditions such as dry eye disease, as well as other conditions, is disclosed. Rapamycin and/or ascomycin is administered intraocularly, such as by topical application, injection into the eye, or implantation in or on the eye. For example, a topical administration may contain between about 50 pg/ml drug to about 50 μg/ml drug in a formulation which may be applied at bedtime or throughout the day. For injection, a dose of about 50 pg/mi to about 200 μg/ml may be used. Rapamycin and/or ascomycin may also be administered in milligram quantities as a surgical implant, for example, in a diffusible walled reservoir sutured to the wall of the sclera, or may be contained within an inert carrier such as microspheres or liposomes to provide a slow-release drug delivery system.

The invention relates to the technical field of medical apparatus, in particular to a drug-release magnesium alloy stent which can be completely degraded and adsorbed, with the period of drug release being about 30 days. The stent is obtained from a magnesium alloy precise tube that is cut through laser; the surface of the stent has a double-layer coating structure, with the inner layer being a temporarily protective layer of a magnesium alloy substrate and the outer layer a degradable polymer film which is mixed with drugs. In addition, the stent is visual in X-ray by means of marks at both sides or on the surface. The drug-release magnesium alloy stent is not only provided with good mechanical property, but also good visibility in X-ray, and can, by the option of slow-release drugs, reduce the restenosis occurrence after being implanted. In addition, the stent can be gradually degraded in and adsorbed by a biosome and used as a stent in a cardiovascular system or other cavities.

The present invention is directed to a novel short term slow release drug delivery system, preferably for solid oral dosage forms of water-soluble, alkaline salts of alkali metals and alkaline earth metals comprising polyvinylpyrrolidone and CPAA and preferably a wax component.

The invention discloses a long acting slow-release drug carrier material for therapy and repair of bone disease and preparation method; wherein, the components of the drug carrier material are 4-8 weight account of strontium-doped calcium polyphosphate, 1-3 weight account of chitosan drug-loaded microspheres and 1-3 weight account of chitosan; the preparation method of the compound drug carrier material for therapy of osteomyelitis and other bone diseases is that (1) the chitosan-acetic acid solution is prepared, (2) the strontium-doped calcium polyphosphate powder is put into the chitosan-acetic acid solution and dispersed evenly, (3) the prepared chitosan drug-loaded microspheres is added, (4) the cross-linking agent is added for cross-linking, (5) freezing at temperature of 2-6 DEG C is processed for 12-48 hours, and (6) heating and drying are processed at temperature of 40-100 DEG C. The drug carrier material has the advantages of being applicable to therapy and repair of osteomyelitis and other bone diseases, releasing antibiotic for a long period, bone repair function, good biocompatibility and degradability, and ideal double function of therapy and repair of osteomyelitis and other bone diseases.

The invention provides a biodegradable cardia support. The biodegradable cardia support comprises a biodegradable support framework which is formed by weave of biodegradable high polymer material filaments, and a layer of controlled-release drug layer is coated on the surface of the biodegradable support framework. The support framework and drug carriers are made of high polymer biodegradable materials and can fully and automatically degradate after time window treatment is finished, and therefore the trouble of taking out the support is avoided. In addition, the controlled-release drug layer can release anti-inflammatory drugs stably through drug controlled-release technology, and therefore fibroblast hyperplasia caused by esophagus repair reaction can be effectively restrained, subsequent scar tissue hyperplasia and thickening can be reduced, and tissue hyperplasia on the surface of the support after the support is implanted is restrained. Thus, the time window of support implantation treatment can be prolonged, supporting force of the support on tube walls can be increased, and long-dated reappearance can be reduced.

An intraosseous fixation implant and a preparation method therefor. In the intraosseous fixation implant, a biodegradable polymer material is used as a substrate, a drug coating is loaded on the surface of the substrate, the drug coating has a double-layer structure, the first layer close to the substrate is a slow-release drug layer, and the second layer on the outer side of the first layer is a quick-release hydrophilic layer. The intraosseous fixation implant has triple functions of being antibacterial, absorbable and fixable.

The invention belongs to the technical field of medicines, and particularly discloses a composition and a preparation method of cyclic dinucleotide cGAMP (cyclic Guanosine Adenosine Monophosphate) encapsulated by a targeting liposome and application of the cyclic dinucleotide cGAMP to anti-tumor. The targeting liposome consists of lecithin, cholesterol, polyethylene glycol and the like as well as a link targeting molecule of the targeting liposome; a cGAMP slow release drug encapsulated by the targeting liposome can be used for enhancing the intensifying cell osmosis action, enhancing an immune reaction, effectively targeting drug delivery and intensifying the inhibition on the growth of multiple tumor cells. Therefore, the cGAMP encapsulated by the targeting liposome can be used for preparing an anti-tumor targeting slow release drug, and has important potential application in the field of targeting immune anti-tumor.

A transdermal drug administration device comprising a drug delivery element (10) defining a contact surface (12) for location, in use, against a patient's skin. The drug delivery element (10) includes a sustained-release pharmaceutical composition. The composition comprises a network of a carrier material having a high mechanical strength and an active pharmaceutical ingredient. The active pharmaceutical ingredient is co-formedly interspersed within pores in the solid, continuous network of the carrier material.

The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.

The invention discloses a bactrocera dorsalis slow-release type attractant which includes the following components by mass percent: 80-90% of methyl eugenol, 5-10% of a synergist and 5-15% of a slow-release agent, wherein the synergist adopts one or more of orange oil, psidium guajava essential oil, mango essential oil, loquat flower essential oil and carambola essential oil; the slow-release agent adopts one or more of vegetable oil and gutter oil. The bactrocera dorsalis slow-release type attractant provided by the invention adopts a simple, effective and pollution-free slow-release and synergistic technology, and includes not only methyl eugenol active substances but also plant essential oil which has a synergistic effect, as well as the slow-release drug for increasing the drug effect duration, so as to prolong the attraction time and improve the attraction effect of the bactrocera dorsalis attractant, and satisfy technology requirements for effective and long-lasting prevention and control. The raw materials used by the bactrocera dorsalis slow-release type attractant have the characteristics of being environment-friendly, low in cost and long in drug effect duration.

The invention discloses a method for continuously preparing sodium carboxymethylcellulose (CMC)/graphene oxide (GO) compound hydrogel microspheres with pollutant adsorption and drug sustained release functions. According to the method, a certain proportion of CMC, GO and citric acid (CA, a crosslinking agent) are dispersed into deionized water by virtue of solution blending, and CMC/GO compound microspheres are prepared by virtue of a spray drying method. The prepared compound microspheres have good swelling property and are capable of adsorbing organic dyestuffs and heavy metal ions in industrial wastewater, and the maximum adsorbing capacities are respectively 66mg/g(Eosin Y) and 120mg/g(Cr<6+>). Meanwhile, the compound microspheres can be used as a sustained release drug carrier. The CMC/GO compound hydrogel microspheres are prepared by virtue of spray drying, so that the process is simple; the method is applicable to large-scale industrial production and has good market application prospect in aspects of wide spectrum type adsorbents and sustained release drug carriers.

The present invention relates to a pharmaceutical delivery system comprising a gel-like structure that comprises at least one water-soluble polymer, such as, for example, povidone or hydroxypropyl cellulose, and at least one fatty acid, such as, for example, stearic acid or lauric acid. The invention further relates to a sustained release drug delivery composition comprising the gel-like structure and at least one drug trapped or dissolved therein, wherein said system is capable of releasing the drug in a dissolution medium at a controlled rate. The invention is also directed to a method for preparing the sustained release drug delivery composition.

The invention relates to the field of medicaments, and mainly provides a method for preparing a medicament carrying controlled-release nanometer material and application. In the medicament carrying controlled-release nanometer material, sandwich silicon dioxide nanometer particles are taken as a carrier, and after medicaments are loaded into a cavity, gamma-polyglutamic acid and chitosan serving as outer-layer membranes are coated outside the nanometer material. The medicament carrying controlled-release nanometer material has the high medicament carrying rate, and the gamma-polyglutamic acid membrane and the chitosan serving as the outer-layer membranes can regulate the release of the medicaments in the cavity according to the change of external conditions so as to achieve the effect of releasing the medicament slowly and have certain targeting.

The invention relates to a method for preparing recombinant human growth hormone entrapped sustained-release drug microcapsules. According to the method, a degradable multi-arm polyethylene glycol-polylactic acid block polymer material with good biocompatibility is taken as a vector material, and raw materials are easily obtained; the multi-arm polymer has relatively small hydrodynamic volume and relatively low viscosity, and the degradation rate of the multi-arm polymer is higher than that of linear polymers, so that the loading and delivery of drugs are more facilitated; a multi-arm polyethylene glycol-polylactic acid block copolymer has good drug loading capacity and unique amphiphilicity, so that protein adsorption can be prevented, the recognition and phagocytosis of a reticuloendothelial system are avoided, and the physiological barrier is easy to pass; the method disclosed by the invention is simple and does not need a complicated re-emulsion formation process; the microcapsules are good in stability, the bioavailability of recombinant human growth hormone is improved, and the content of the recombinant human growth hormone reaches up to 46-81%; the entrapment rate of the recombinant human growth hormone entrapped sustained-release drug microcapsules reaches 91%, the stability is good, the grain size is uniform, and the repeatability is good, so that the recombinant human growth hormone entrapped sustained-release drug microcapsules are suitable for large-scale production.